Pre-diagnostic dynamic HPV16 IgG seropositivity and risk of oropharyngeal cancer

Karen Anderson, Garrick Wallstrom, Hilde Langseth, Marshall Posner, Julia N. Cheng, Rizwan Alam, Diego Chowell, Ingegerd E. Furre, Jon Mork

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective The aim of this study was to determine the association of HPV16 antibodies (Abs) and oropharyngeal cancer (OPC) risk in sera obtained prior to clinical diagnosis. Methods We identified 92 participants with incident OPC and 460 matched controls from the Janus Serum Bank Cohort in Norway. Archived tumor specimens were requested for a subset of the cases. Serum samples were collected from cases, on average, 9.3 years before diagnosis (range, 0.1–14.9 years). Ten cases had serum samples from multiple time points. IgG seropositivity to 8 HPV16 antigens was determined, and a logistic regression classifier of a panel of all early-antigen (EA) Abs for the predictive diagnosis of OPC was applied. Results HPV16 EA seropositivity was present in 25.0% of patients with OPC and 7.6% of controls (odds ratio (OR), 4.1; 95% CI, 2.3–7.2, p < 0.0001). Abs to E2 were strongly associated with cases 0–2 years pre- diagnosis (OR, 150.1; 95% CI, 27.4–1040.0, p < 0.0001), and the probability of seropositivity was inversely associated with time to diagnosis (OR, 0.7 per additional year; 95% CI, 0.6–0.9, p = 0.0002). Abs to E2 were also strongly associated with tumor HPV status (OR, 35.6; 95% CI, 8.7–200.0, p < 0.0001). A positive score on the binary classifier was associated with an overall OR of 15.8 (95% CI, 5.6–53.4) compared with controls (p < 0.05), and was strongly associated with tumor HPV status (OR, 27.4; 95% CI, 8.6–99.6, p < 0.001). Conclusions HPV16 Abs are detectable years prior to diagnosis of OPC, and the probability of seropositivity increases closer to diagnosis.

Original languageEnglish (US)
Pages (from-to)132-137
Number of pages6
JournalOral Oncology
Volume73
DOIs
StatePublished - Oct 1 2017

Fingerprint

Oropharyngeal Neoplasms
Immunoglobulin G
Odds Ratio
Antibodies
Serum
Antigens
Neoplasms
Norway
Logistic Models

Keywords

  • Antibodies
  • Biomarker
  • Head and neck cancer
  • HPV
  • Oropharyngeal cancer
  • Serology

ASJC Scopus subject areas

  • Oral Surgery
  • Oncology
  • Cancer Research

Cite this

Anderson, K., Wallstrom, G., Langseth, H., Posner, M., Cheng, J. N., Alam, R., ... Mork, J. (2017). Pre-diagnostic dynamic HPV16 IgG seropositivity and risk of oropharyngeal cancer. Oral Oncology, 73, 132-137. https://doi.org/10.1016/j.oraloncology.2017.08.014

Pre-diagnostic dynamic HPV16 IgG seropositivity and risk of oropharyngeal cancer. / Anderson, Karen; Wallstrom, Garrick; Langseth, Hilde; Posner, Marshall; Cheng, Julia N.; Alam, Rizwan; Chowell, Diego; Furre, Ingegerd E.; Mork, Jon.

In: Oral Oncology, Vol. 73, 01.10.2017, p. 132-137.

Research output: Contribution to journalArticle

Anderson, K, Wallstrom, G, Langseth, H, Posner, M, Cheng, JN, Alam, R, Chowell, D, Furre, IE & Mork, J 2017, 'Pre-diagnostic dynamic HPV16 IgG seropositivity and risk of oropharyngeal cancer' Oral Oncology, vol. 73, pp. 132-137. https://doi.org/10.1016/j.oraloncology.2017.08.014
Anderson, Karen ; Wallstrom, Garrick ; Langseth, Hilde ; Posner, Marshall ; Cheng, Julia N. ; Alam, Rizwan ; Chowell, Diego ; Furre, Ingegerd E. ; Mork, Jon. / Pre-diagnostic dynamic HPV16 IgG seropositivity and risk of oropharyngeal cancer. In: Oral Oncology. 2017 ; Vol. 73. pp. 132-137.
@article{599f898655764b658a0ee47aec9a341e,
title = "Pre-diagnostic dynamic HPV16 IgG seropositivity and risk of oropharyngeal cancer",
abstract = "Objective The aim of this study was to determine the association of HPV16 antibodies (Abs) and oropharyngeal cancer (OPC) risk in sera obtained prior to clinical diagnosis. Methods We identified 92 participants with incident OPC and 460 matched controls from the Janus Serum Bank Cohort in Norway. Archived tumor specimens were requested for a subset of the cases. Serum samples were collected from cases, on average, 9.3 years before diagnosis (range, 0.1–14.9 years). Ten cases had serum samples from multiple time points. IgG seropositivity to 8 HPV16 antigens was determined, and a logistic regression classifier of a panel of all early-antigen (EA) Abs for the predictive diagnosis of OPC was applied. Results HPV16 EA seropositivity was present in 25.0{\%} of patients with OPC and 7.6{\%} of controls (odds ratio (OR), 4.1; 95{\%} CI, 2.3–7.2, p < 0.0001). Abs to E2 were strongly associated with cases 0–2 years pre- diagnosis (OR, 150.1; 95{\%} CI, 27.4–1040.0, p < 0.0001), and the probability of seropositivity was inversely associated with time to diagnosis (OR, 0.7 per additional year; 95{\%} CI, 0.6–0.9, p = 0.0002). Abs to E2 were also strongly associated with tumor HPV status (OR, 35.6; 95{\%} CI, 8.7–200.0, p < 0.0001). A positive score on the binary classifier was associated with an overall OR of 15.8 (95{\%} CI, 5.6–53.4) compared with controls (p < 0.05), and was strongly associated with tumor HPV status (OR, 27.4; 95{\%} CI, 8.6–99.6, p < 0.001). Conclusions HPV16 Abs are detectable years prior to diagnosis of OPC, and the probability of seropositivity increases closer to diagnosis.",
keywords = "Antibodies, Biomarker, Head and neck cancer, HPV, Oropharyngeal cancer, Serology",
author = "Karen Anderson and Garrick Wallstrom and Hilde Langseth and Marshall Posner and Cheng, {Julia N.} and Rizwan Alam and Diego Chowell and Furre, {Ingegerd E.} and Jon Mork",
year = "2017",
month = "10",
day = "1",
doi = "10.1016/j.oraloncology.2017.08.014",
language = "English (US)",
volume = "73",
pages = "132--137",
journal = "Oral Oncology",
issn = "1368-8375",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Pre-diagnostic dynamic HPV16 IgG seropositivity and risk of oropharyngeal cancer

AU - Anderson, Karen

AU - Wallstrom, Garrick

AU - Langseth, Hilde

AU - Posner, Marshall

AU - Cheng, Julia N.

AU - Alam, Rizwan

AU - Chowell, Diego

AU - Furre, Ingegerd E.

AU - Mork, Jon

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Objective The aim of this study was to determine the association of HPV16 antibodies (Abs) and oropharyngeal cancer (OPC) risk in sera obtained prior to clinical diagnosis. Methods We identified 92 participants with incident OPC and 460 matched controls from the Janus Serum Bank Cohort in Norway. Archived tumor specimens were requested for a subset of the cases. Serum samples were collected from cases, on average, 9.3 years before diagnosis (range, 0.1–14.9 years). Ten cases had serum samples from multiple time points. IgG seropositivity to 8 HPV16 antigens was determined, and a logistic regression classifier of a panel of all early-antigen (EA) Abs for the predictive diagnosis of OPC was applied. Results HPV16 EA seropositivity was present in 25.0% of patients with OPC and 7.6% of controls (odds ratio (OR), 4.1; 95% CI, 2.3–7.2, p < 0.0001). Abs to E2 were strongly associated with cases 0–2 years pre- diagnosis (OR, 150.1; 95% CI, 27.4–1040.0, p < 0.0001), and the probability of seropositivity was inversely associated with time to diagnosis (OR, 0.7 per additional year; 95% CI, 0.6–0.9, p = 0.0002). Abs to E2 were also strongly associated with tumor HPV status (OR, 35.6; 95% CI, 8.7–200.0, p < 0.0001). A positive score on the binary classifier was associated with an overall OR of 15.8 (95% CI, 5.6–53.4) compared with controls (p < 0.05), and was strongly associated with tumor HPV status (OR, 27.4; 95% CI, 8.6–99.6, p < 0.001). Conclusions HPV16 Abs are detectable years prior to diagnosis of OPC, and the probability of seropositivity increases closer to diagnosis.

AB - Objective The aim of this study was to determine the association of HPV16 antibodies (Abs) and oropharyngeal cancer (OPC) risk in sera obtained prior to clinical diagnosis. Methods We identified 92 participants with incident OPC and 460 matched controls from the Janus Serum Bank Cohort in Norway. Archived tumor specimens were requested for a subset of the cases. Serum samples were collected from cases, on average, 9.3 years before diagnosis (range, 0.1–14.9 years). Ten cases had serum samples from multiple time points. IgG seropositivity to 8 HPV16 antigens was determined, and a logistic regression classifier of a panel of all early-antigen (EA) Abs for the predictive diagnosis of OPC was applied. Results HPV16 EA seropositivity was present in 25.0% of patients with OPC and 7.6% of controls (odds ratio (OR), 4.1; 95% CI, 2.3–7.2, p < 0.0001). Abs to E2 were strongly associated with cases 0–2 years pre- diagnosis (OR, 150.1; 95% CI, 27.4–1040.0, p < 0.0001), and the probability of seropositivity was inversely associated with time to diagnosis (OR, 0.7 per additional year; 95% CI, 0.6–0.9, p = 0.0002). Abs to E2 were also strongly associated with tumor HPV status (OR, 35.6; 95% CI, 8.7–200.0, p < 0.0001). A positive score on the binary classifier was associated with an overall OR of 15.8 (95% CI, 5.6–53.4) compared with controls (p < 0.05), and was strongly associated with tumor HPV status (OR, 27.4; 95% CI, 8.6–99.6, p < 0.001). Conclusions HPV16 Abs are detectable years prior to diagnosis of OPC, and the probability of seropositivity increases closer to diagnosis.

KW - Antibodies

KW - Biomarker

KW - Head and neck cancer

KW - HPV

KW - Oropharyngeal cancer

KW - Serology

UR - http://www.scopus.com/inward/record.url?scp=85029597383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029597383&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2017.08.014

DO - 10.1016/j.oraloncology.2017.08.014

M3 - Article

VL - 73

SP - 132

EP - 137

JO - Oral Oncology

JF - Oral Oncology

SN - 1368-8375

ER -